Skip to main content
Top
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation

Authors: Dagmar Quandt, Simon Jasinski-Bergner, Ulrike Müller, Bianca Schulze, Barbara Seliger

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

The importance of B7-H molecules for the T cell/tumor communication and its impact on renal cell carcinoma (RCC) progression and prognosis has been recently described. Cytokine treatment of RCC has earlier been shown to be beneficial in preclinical settings, but its clinical implementation has not proven to be as effective. This might be partially explained by the yet incomplete picture of cellular alterations in tumor cells upon cytokine treatment investigated in detail in this study.

Methods

RCC tumor cell lines were treated with different cytokines alone or in combination. The constitutive and/or cytokine-induced expression of cytokine receptors signaling components and B7-H molecules in RCC cells were analysed by qPCR and flow cytometry. A mcherry reporter gene construct containing B7-H1 promoter was cloned and its activity was determined upon transfection in cytokine-stimulated cells. Cytokine pretreated tumor cells were co-cultured with allogeneic CD8+ T cells from healthy donors and T cell proliferation as well as cytokine secretion was determined.

Results

A heterogeneous, but constitutive B7-H1,-H2,-H3 and H4 expression was found on human RCC cell lines. IL-4 and TNFα treatment led to strong synergistic induction of B7-H1 in RCC cells, whereas B7-H2 was only increased by TNFα. In contrast, B7-H3 and B7-H4 expression were not altered by these cytokines. Treatment of RCC cells with TNFα and IL-4 was accompanied by an activation of signaling molecules like NF-κB, IκB and STAT6. The cytokine-mediated up-regulation of B7-H1 was due to transcriptional control as determined by an increased B7-H1 promoter activity in the presence of IL-4 and TNFα. Despite HLA class I and LFA-1 were also increased, the cytokine-mediated up-regulation of B7-H1 was more pronounced and caused an inhibition of allospecifc CD8+ T cell proliferation.

Conclusion

Thus, IL-4 and TNFα, which could be released by immune cells of the tumor microenvironment, are able to control the B7-H1 expression in RCC thereby altering T cell responses. These data are of importance for understanding the complex interplay of tumor cells with immune cells orchestrated by a number of different soluble and membrane bound mediators and for the implementation of check point antibodies directed against B7-H1.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed
3.
go back to reference Escudier B: Emerging immunotherapies for renal cell carcinoma. Ann Oncol. 2012, 23 (8): 35-40. Escudier B: Emerging immunotherapies for renal cell carcinoma. Ann Oncol. 2012, 23 (8): 35-40.
4.
go back to reference Seliger B, Quandt D: The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother. 2012, 61: 1327-1341. 10.1007/s00262-012-1293-6.CrossRefPubMed Seliger B, Quandt D: The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother. 2012, 61: 1327-1341. 10.1007/s00262-012-1293-6.CrossRefPubMed
5.
go back to reference Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008, 111: 3635-3643. 10.1182/blood-2007-11-123141.PubMedCentralCrossRefPubMed Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008, 111: 3635-3643. 10.1182/blood-2007-11-123141.PubMedCentralCrossRefPubMed
6.
go back to reference Kaifu T, Escaliere B, Gastinel LN, Vivier E, Baratin M: B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci. 2011, 68: 3531-3539. 10.1007/s00018-011-0802-7.CrossRefPubMed Kaifu T, Escaliere B, Gastinel LN, Vivier E, Baratin M: B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci. 2011, 68: 3531-3539. 10.1007/s00018-011-0802-7.CrossRefPubMed
7.
go back to reference Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol. 2005, 23: 515-548. 10.1146/annurev.immunol.23.021704.115611.CrossRefPubMed Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol. 2005, 23: 515-548. 10.1146/annurev.immunol.23.021704.115611.CrossRefPubMed
8.
go back to reference Tang PA, Heng DY: Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep. 2013, 15: 98-104. 10.1007/s11912-012-0284-2.CrossRefPubMed Tang PA, Heng DY: Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep. 2013, 15: 98-104. 10.1007/s11912-012-0284-2.CrossRefPubMed
9.
go back to reference Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006, 66: 3381-3385. 10.1158/0008-5472.CAN-05-4303.CrossRefPubMed Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006, 66: 3381-3385. 10.1158/0008-5472.CAN-05-4303.CrossRefPubMed
10.
go back to reference Sanjmyatav J, Steiner T, Wunderlich H, Diegmann J, Gajda M, Junker K: A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma. J Urol. 2011, 186: 289-294. 10.1016/j.juro.2011.03.033.CrossRefPubMed Sanjmyatav J, Steiner T, Wunderlich H, Diegmann J, Gajda M, Junker K: A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma. J Urol. 2011, 186: 289-294. 10.1016/j.juro.2011.03.033.CrossRefPubMed
11.
go back to reference Smith AJ, Humphries SE: Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev. 2009, 20: 43-59. 10.1016/j.cytogfr.2008.11.006.CrossRefPubMed Smith AJ, Humphries SE: Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev. 2009, 20: 43-59. 10.1016/j.cytogfr.2008.11.006.CrossRefPubMed
12.
go back to reference Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E, Wuest T, Stenner F, Perani A, Cohen L, Knuth A, Divgi C, Jager D, Scott AM, Ritter G, Old LJ, Renner C: Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int J Cancer. 2009, 125: 115-123. 10.1002/ijc.24359.CrossRefPubMed Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E, Wuest T, Stenner F, Perani A, Cohen L, Knuth A, Divgi C, Jager D, Scott AM, Ritter G, Old LJ, Renner C: Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int J Cancer. 2009, 125: 115-123. 10.1002/ijc.24359.CrossRefPubMed
13.
go back to reference Hoon DS, Okun E, Banez M, Irie RF, Morton DL: Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas. Cancer Res. 1991, 51: 5687-5693.PubMed Hoon DS, Okun E, Banez M, Irie RF, Morton DL: Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas. Cancer Res. 1991, 51: 5687-5693.PubMed
14.
go back to reference Ikemoto S, Narita K, Yoshida N, Wada S, Kishimoto T, Sugimura K, Nakatani T: Effects of tumor necrosis factor alpha in renal cell carcinoma. Oncol Rep. 2003, 10: 1947-1955.PubMed Ikemoto S, Narita K, Yoshida N, Wada S, Kishimoto T, Sugimura K, Nakatani T: Effects of tumor necrosis factor alpha in renal cell carcinoma. Oncol Rep. 2003, 10: 1947-1955.PubMed
15.
go back to reference Bockorny B, Dasanu CA: Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol Ther. 2013, 13: 911-925. 10.1517/14712598.2013.778970.CrossRefPubMed Bockorny B, Dasanu CA: Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol Ther. 2013, 13: 911-925. 10.1517/14712598.2013.778970.CrossRefPubMed
16.
go back to reference Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW: Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother Emphasis Tumor Immunol. 1994, 15: 147-153. 10.1097/00002371-199402000-00009.CrossRefPubMed Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW: Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother Emphasis Tumor Immunol. 1994, 15: 147-153. 10.1097/00002371-199402000-00009.CrossRefPubMed
17.
go back to reference Motzer RJ, Russo P, Nanus DM, Berg WJ: Renal cell carcinoma. Curr Probl Cancer. 1997, 21: 185-232. 10.1016/S0147-0272(97)80007-4.CrossRefPubMed Motzer RJ, Russo P, Nanus DM, Berg WJ: Renal cell carcinoma. Curr Probl Cancer. 1997, 21: 185-232. 10.1016/S0147-0272(97)80007-4.CrossRefPubMed
18.
go back to reference Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR, Crawford ED: Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a Southwest oncology group study. J Immunother. 2002, 25: 352-358. 10.1097/00002371-200207000-00007.CrossRefPubMed Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR, Crawford ED: Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a Southwest oncology group study. J Immunother. 2002, 25: 352-358. 10.1097/00002371-200207000-00007.CrossRefPubMed
19.
go back to reference Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A: Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006, 119: 317-327. 10.1002/ijc.21775.CrossRefPubMed Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A: Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006, 119: 317-327. 10.1002/ijc.21775.CrossRefPubMed
20.
go back to reference Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M, Shinya E, Takahashi H, Tamada K, Chen L, Dan K, Ogata K: Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood. 2010, 116: 1124-1131. 10.1182/blood-2009-12-255125.PubMedCentralCrossRefPubMed Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M, Shinya E, Takahashi H, Tamada K, Chen L, Dan K, Ogata K: Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood. 2010, 116: 1124-1131. 10.1182/blood-2009-12-255125.PubMedCentralCrossRefPubMed
21.
go back to reference Quandt D, Fiedler E, Boettcher D, Marsch W, Seliger B: B7-h4 expression in human melanoma: its association with patients’ survival and antitumor immune response. Clin Cancer Res. 2011, 17: 3100-3111. 10.1158/1078-0432.CCR-10-2268.CrossRefPubMed Quandt D, Fiedler E, Boettcher D, Marsch W, Seliger B: B7-h4 expression in human melanoma: its association with patients’ survival and antitumor immune response. Clin Cancer Res. 2011, 17: 3100-3111. 10.1158/1078-0432.CCR-10-2268.CrossRefPubMed
22.
go back to reference Wulfanger J, Biehl K, Tetzner A, Wild P, Ikenberg K, Meyer S, Seliger B: Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma. Int J Cancer. 2013, 133: 2522-2532.PubMed Wulfanger J, Biehl K, Tetzner A, Wild P, Ikenberg K, Meyer S, Seliger B: Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma. Int J Cancer. 2013, 133: 2522-2532.PubMed
23.
go back to reference Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B: Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem. 2010, 285: 30419-30426. 10.1074/jbc.M109.094284.PubMedCentralCrossRefPubMed Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B: Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem. 2010, 285: 30419-30426. 10.1074/jbc.M109.094284.PubMedCentralCrossRefPubMed
24.
go back to reference Chen Y, Zhang J, Guo G, Ruan Z, Jiang M, Wu S, Guo S, Fei L, Tang Y, Yang C, Jia Z, Wu Y: Induced B7-H1 expression on human renal tubular epithelial cells by the sublytic terminal complement complex C5b-9. Mol Immunol. 2009, 46: 375-383. 10.1016/j.molimm.2008.10.026.CrossRefPubMed Chen Y, Zhang J, Guo G, Ruan Z, Jiang M, Wu S, Guo S, Fei L, Tang Y, Yang C, Jia Z, Wu Y: Induced B7-H1 expression on human renal tubular epithelial cells by the sublytic terminal complement complex C5b-9. Mol Immunol. 2009, 46: 375-383. 10.1016/j.molimm.2008.10.026.CrossRefPubMed
25.
go back to reference Steven A, Leisz S, Massa C, Iezzi M, Lattanzio R, Lamolinara A, Bukur J, Muller A, Hiebl B, Holzhausen HJ, Seliger B: HER-2/neu mediates oncogenic transformation via altered CREB expression and function. Mol Cancer Res. 2013, 11: 1462-1477. 10.1158/1541-7786.MCR-13-0125.CrossRefPubMed Steven A, Leisz S, Massa C, Iezzi M, Lattanzio R, Lamolinara A, Bukur J, Muller A, Hiebl B, Holzhausen HJ, Seliger B: HER-2/neu mediates oncogenic transformation via altered CREB expression and function. Mol Cancer Res. 2013, 11: 1462-1477. 10.1158/1541-7786.MCR-13-0125.CrossRefPubMed
26.
go back to reference Falkensammer C, Johrer K, Gander H, Ramoner R, Putz T, Rahm A, Greil R, Bartsch G, Thurnher M: IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses. Cancer Immunol Immunother. 2006, 55: 1228-1237. 10.1007/s00262-006-0122-1.CrossRefPubMed Falkensammer C, Johrer K, Gander H, Ramoner R, Putz T, Rahm A, Greil R, Bartsch G, Thurnher M: IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses. Cancer Immunol Immunother. 2006, 55: 1228-1237. 10.1007/s00262-006-0122-1.CrossRefPubMed
27.
go back to reference Waddick KG, Uckun FM: Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target. Biochem Pharmacol. 1998, 56: 1411-1426. 10.1016/S0006-2952(98)00211-1.CrossRefPubMed Waddick KG, Uckun FM: Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target. Biochem Pharmacol. 1998, 56: 1411-1426. 10.1016/S0006-2952(98)00211-1.CrossRefPubMed
28.
go back to reference Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002, 8: 793-800.CrossRefPubMed Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002, 8: 793-800.CrossRefPubMed
29.
go back to reference Kochli C, Wendland T, Frutig K, Grunow R, Merlin S, Pichler WJ: CD80 and CD86 costimulatory molecules on circulating T cells of HIV infected individuals. Immunol Lett. 1999, 65: 197-201. 10.1016/S0165-2478(98)00107-2.CrossRefPubMed Kochli C, Wendland T, Frutig K, Grunow R, Merlin S, Pichler WJ: CD80 and CD86 costimulatory molecules on circulating T cells of HIV infected individuals. Immunol Lett. 1999, 65: 197-201. 10.1016/S0165-2478(98)00107-2.CrossRefPubMed
30.
go back to reference Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ: Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007, 27: 111-122. 10.1016/j.immuni.2007.05.016.PubMedCentralCrossRefPubMed Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ: Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007, 27: 111-122. 10.1016/j.immuni.2007.05.016.PubMedCentralCrossRefPubMed
31.
go back to reference Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED: Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008, 14: 5150-5157. 10.1158/1078-0432.CCR-08-0536.PubMedCentralCrossRefPubMed Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED: Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008, 14: 5150-5157. 10.1158/1078-0432.CCR-08-0536.PubMedCentralCrossRefPubMed
32.
go back to reference Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED: B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006, 103: 10391-10396. 10.1073/pnas.0600937103.PubMedCentralCrossRefPubMed Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED: B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006, 103: 10391-10396. 10.1073/pnas.0600937103.PubMedCentralCrossRefPubMed
33.
go back to reference Schreiner B, Wischhusen J, Mitsdoerffer M, Schneider D, Bornemann A, Melms A, Tolosa E, Weller M, Wiendl H: Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia. 2003, 44: 296-301. 10.1002/glia.10291.CrossRefPubMed Schreiner B, Wischhusen J, Mitsdoerffer M, Schneider D, Bornemann A, Melms A, Tolosa E, Weller M, Wiendl H: Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia. 2003, 44: 296-301. 10.1002/glia.10291.CrossRefPubMed
34.
go back to reference Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL: Expression of ICOS on human melanoma-infiltrating CD4 + CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol. 2008, 180: 2967-2980. 10.4049/jimmunol.180.5.2967.CrossRefPubMed Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL: Expression of ICOS on human melanoma-infiltrating CD4 + CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol. 2008, 180: 2967-2980. 10.4049/jimmunol.180.5.2967.CrossRefPubMed
35.
go back to reference Wallin JJ, Liang L, Bakardjiev A, Sha WC: Enhancement of CD8+ T cell responses by ICOS/B7h costimulation. J Immunol. 2001, 167: 132-139. 10.4049/jimmunol.167.1.132.CrossRefPubMed Wallin JJ, Liang L, Bakardjiev A, Sha WC: Enhancement of CD8+ T cell responses by ICOS/B7h costimulation. J Immunol. 2001, 167: 132-139. 10.4049/jimmunol.167.1.132.CrossRefPubMed
36.
go back to reference Mizutani Y, Bonavida B, Nio Y, Yoshida O: Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J Urol. 1994, 151: 1697-1702.PubMed Mizutani Y, Bonavida B, Nio Y, Yoshida O: Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J Urol. 1994, 151: 1697-1702.PubMed
37.
go back to reference Obiri NI, Puri RK: Characterization of interleukin-4 receptors expressed on human renal cell carcinoma cells. Oncol Res. 1994, 6: 419-427.PubMed Obiri NI, Puri RK: Characterization of interleukin-4 receptors expressed on human renal cell carcinoma cells. Oncol Res. 1994, 6: 419-427.PubMed
38.
go back to reference Al-Lamki RS, Sadler TJ, Wang J, Reid MJ, Warren AY, Movassagh M, Lu W, Mills IG, Neal DE, Burge J, Vandenebeele P, Pober JS, Bradley JR: Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol. 2010, 177: 943-954. 10.2353/ajpath.2010.091218.PubMedCentralCrossRefPubMed Al-Lamki RS, Sadler TJ, Wang J, Reid MJ, Warren AY, Movassagh M, Lu W, Mills IG, Neal DE, Burge J, Vandenebeele P, Pober JS, Bradley JR: Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol. 2010, 177: 943-954. 10.2353/ajpath.2010.091218.PubMedCentralCrossRefPubMed
39.
go back to reference Varricchio F, Obiri NI, Haas GP, Puri RK: Immunostaining of interleukin-4 receptor on human renal cell carcinoma. Lymphokine Cytokine Res. 1993, 12: 465-469.PubMed Varricchio F, Obiri NI, Haas GP, Puri RK: Immunostaining of interleukin-4 receptor on human renal cell carcinoma. Lymphokine Cytokine Res. 1993, 12: 465-469.PubMed
40.
go back to reference Ikemoto S, Yoshida N, Narita K, Wada S, Kishimoto T, Sugimura K, Nakatani T: Role of tumor-associated macrophages in renal cell carcinoma. Oncol Rep. 2003, 10: 1843-1849.PubMed Ikemoto S, Yoshida N, Narita K, Wada S, Kishimoto T, Sugimura K, Nakatani T: Role of tumor-associated macrophages in renal cell carcinoma. Oncol Rep. 2003, 10: 1843-1849.PubMed
41.
go back to reference Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S: Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2013, 62: 1757-1768. 10.1007/s00262-013-1487-6.CrossRefPubMed Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S: Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2013, 62: 1757-1768. 10.1007/s00262-013-1487-6.CrossRefPubMed
42.
go back to reference Pardoll DM, Topalian SL: The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 1998, 10: 588-594. 10.1016/S0952-7915(98)80228-8.CrossRefPubMed Pardoll DM, Topalian SL: The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 1998, 10: 588-594. 10.1016/S0952-7915(98)80228-8.CrossRefPubMed
43.
go back to reference Zhu J, Ju X, Yan F, Qin C, Wang M, Ding Q, Zhang Z, Yin C: Association of IL-4 -590 T>C polymorphism and risk of renal cell carcinoma in a Chinese population. Int J Immunogenet. 2010, 37: 459-465. 10.1111/j.1744-313X.2010.00948.x.CrossRefPubMed Zhu J, Ju X, Yan F, Qin C, Wang M, Ding Q, Zhang Z, Yin C: Association of IL-4 -590 T>C polymorphism and risk of renal cell carcinoma in a Chinese population. Int J Immunogenet. 2010, 37: 459-465. 10.1111/j.1744-313X.2010.00948.x.CrossRefPubMed
44.
go back to reference Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R: Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol. 2007, 25: 845-851. 10.1200/JCO.2006.07.8154.CrossRefPubMed Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R: Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol. 2007, 25: 845-851. 10.1200/JCO.2006.07.8154.CrossRefPubMed
45.
go back to reference Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006, 203: 871-881. 10.1084/jem.20050930.PubMedCentralCrossRefPubMed Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006, 203: 871-881. 10.1084/jem.20050930.PubMedCentralCrossRefPubMed
46.
go back to reference Swallow MM, Wallin JJ, Sha WC: B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity. 1999, 11: 423-432. 10.1016/S1074-7613(00)80117-X.CrossRefPubMed Swallow MM, Wallin JJ, Sha WC: B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity. 1999, 11: 423-432. 10.1016/S1074-7613(00)80117-X.CrossRefPubMed
47.
go back to reference Youngnak-Piboonratanakit P, Tsushima F, Otsuki N, Igarashi H, Omura K, Azuma M: Expression and regulation of human CD275 on endothelial cells in healthy and inflamed mucosal tissues. Scand J Immunol. 2006, 63: 191-198. 10.1111/j.1365-3083.2006.01726.x.CrossRefPubMed Youngnak-Piboonratanakit P, Tsushima F, Otsuki N, Igarashi H, Omura K, Azuma M: Expression and regulation of human CD275 on endothelial cells in healthy and inflamed mucosal tissues. Scand J Immunol. 2006, 63: 191-198. 10.1111/j.1365-3083.2006.01726.x.CrossRefPubMed
48.
go back to reference Mazanet MM, Hughes CC: B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol. 2002, 169: 3581-3588. 10.4049/jimmunol.169.7.3581.CrossRefPubMed Mazanet MM, Hughes CC: B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol. 2002, 169: 3581-3588. 10.4049/jimmunol.169.7.3581.CrossRefPubMed
49.
go back to reference Makgoba MW, Sanders ME, Shaw S: The CD2-LFA-3 and LFA-1-ICAM pathways: relevance to T-cell recognition. Immunol Today. 1989, 10: 417-422. 10.1016/0167-5699(89)90039-X.CrossRefPubMed Makgoba MW, Sanders ME, Shaw S: The CD2-LFA-3 and LFA-1-ICAM pathways: relevance to T-cell recognition. Immunol Today. 1989, 10: 417-422. 10.1016/0167-5699(89)90039-X.CrossRefPubMed
50.
go back to reference Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED: PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007, 13: 1757-1761. 10.1158/1078-0432.CCR-06-2599.CrossRefPubMed Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED: PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007, 13: 1757-1761. 10.1158/1078-0432.CCR-06-2599.CrossRefPubMed
51.
go back to reference Pfistershammer K, Klauser C, Pickl WF, Stockl J, Leitner J, Zlabinger G, Majdic O, Steinberger P: No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol. 2006, 36: 1104-1113. 10.1002/eji.200535344.PubMedCentralCrossRefPubMed Pfistershammer K, Klauser C, Pickl WF, Stockl J, Leitner J, Zlabinger G, Majdic O, Steinberger P: No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol. 2006, 36: 1104-1113. 10.1002/eji.200535344.PubMedCentralCrossRefPubMed
52.
go back to reference Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001, 2: 261-268. 10.1038/85330.CrossRefPubMed Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001, 2: 261-268. 10.1038/85330.CrossRefPubMed
53.
go back to reference Loke P, Allison JP: PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003, 100: 5336-5341. 10.1073/pnas.0931259100.PubMedCentralCrossRefPubMed Loke P, Allison JP: PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003, 100: 5336-5341. 10.1073/pnas.0931259100.PubMedCentralCrossRefPubMed
54.
go back to reference Lejeune FJ, Ruegg C, Lienard D: Clinical applications of TNF-alpha in cancer. Curr Opin Immunol. 1998, 10: 573-580. 10.1016/S0952-7915(98)80226-4.CrossRefPubMed Lejeune FJ, Ruegg C, Lienard D: Clinical applications of TNF-alpha in cancer. Curr Opin Immunol. 1998, 10: 573-580. 10.1016/S0952-7915(98)80226-4.CrossRefPubMed
Metadata
Title
Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation
Authors
Dagmar Quandt
Simon Jasinski-Bergner
Ulrike Müller
Bianca Schulze
Barbara Seliger
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-151

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.